Genentech and Biogen’s $122 Million Royalty Dispute Ends in Mistrial, Judge Considers Bench Trial

In a high-stakes legal battle between Genentech Inc. and Biogen MA Inc., a California federal judge declared a mistrial after jurors reached a stalemate in a $122 million breach of contract case concerning patent royalties linked to a multiple sclerosis drug. The impasse led the judge to express openness to Genentech’s proposal to forgo a jury in a potential retrial. This development marks a significant turn in the contentious disagreement between the two pharmaceutical giants over royalties pertaining to sales of the medicine. For further reading, access the original source article.